- Home
- RLTY vs FENC Comparison
RLTY vs FENC Comparison
Compare RLTY & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$6.72
Company Overview
Basic Information| Metric | RLTY | FENC |
|---|---|---|
| Founded | 2022 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.8M | 266.4M |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | RLTY | FENC |
|---|---|---|
| Price | $15.75 | $6.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 45.1K | ★ 126.2K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 9.35% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.04 | $5.65 |
| 52 Week High | $15.97 | $9.92 |
Technical Indicators
Market Signals| Indicator | RLTY | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 65.28 | 50.65 |
| Support Level | $14.93 | $5.65 |
| Resistance Level | N/A | $8.09 |
| Average True Range (ATR) | 0.20 | 0.33 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 98.18 | 58.71 |
Price Performance
Historical Comparison RLTY
FENC
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.